Dogma s Oral PCSK9 Inhibitor Program - Ownership and Business Overview

Life ScienceCompany

Dogma s Oral PCSK9 Inhibitor Program Ownership

Who owns Dogma s Oral PCSK9 Inhibitor Program?

Dogma s Oral PCSK9 Inhibitor Program is owned by AstraZeneca. It was acquired on September 17, 2020.

Dogma s Oral PCSK9 Inhibitor Program Business Overview

Where is Dogma s Oral PCSK9 Inhibitor Program headquartered?

Dogma s Oral PCSK9 Inhibitor Program is headquartered in Boxford, Massachusetts.

What sector is Dogma s Oral PCSK9 Inhibitor Program in?

Dogma s Oral PCSK9 Inhibitor Program is a life science company.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 290 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 267 by strategics.

Dogma's Oral PCSK9 Inhibitor Program

Boxford, Massachusetts
United States,

Dogma's Oral PCSK9 Inhibitor Program is a protein that regulates the level of low-density lipoprotein (LDL) or ‘bad’ cholesterol in the blood. Increased activity of PCSK9 is associated with high LDL cholesterol.


Company Summary

SECTOR

Life Science

 Subscribe to unlock this and 208,848
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Dogma s Oral PCSK9 Inhibitor Program

Massachusetts Companies , Life Science Companies , United States Companies , Massachusetts Life Science Companies , Massachusetts Life Science with Acquisitions , Massachusetts Life Science with Divestitures

Related Lists for Massachusetts Companies

Largest Massachusetts Companies , Acquisitive Massachusetts Companies , Recently Acquired Massachusetts Companies , Recently Sold Massachusetts Companies , Private Massachusetts Companies , Public Massachusetts Companies , Acquired Massachusetts Companies , PE Backed Massachusetts Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United States Companies

Largest United States Companies , Acquisitive United States Companies , Recently Acquired United States Companies , Recently Sold United States Companies , Private United States Companies , Public United States Companies , Acquired United States Companies , PE Backed United States Companies
Mergr

Product

Company

Legal